Interview with P.F. Bongers, Chairman, Bogin
Having one of the highest penetration rates in Europe, generic medicines play a very important role in the Dutch pharmaceutical market. As this is the principal association for the generics…
Address: Wilgenlaan 5 • 1161 JK Zwanenburg,Netherlands
Tel: 31 (0) 20 / 407 20 72
Web: http://www.daiichi-sankyo.nl/
DAIICHI SANKYO’s goal is to establish itself as a ‘Global Pharma Innovator.’ The pharmaceutical industry is one of the 21st century’s growth industries, and what this vision of the company signifies is DAIICHI SANKYO making it the leading industry of Japan, a nation built on the platform of scientific and technological creativity, and establishing itself as a firm presence by continued success as a flagship company. This is the vision that guides the development of our global pharmaceutical operations.
DAIICHI SANKYO’s products are used not only in Japan but also in many parts of the world including Asia, Europe and the United States. To pick up on global needs all over the world and have these reflected in global pharmaceutical operations, we are active in promoting information exchange in a number of areas including research and development, supply chain management and marketing.
We are determined to contribute to the health of people everywhere by creating new medicines in popular use throughout the world, and delivering them to places where medical treatment is required, transcending national borders.
We have about 2,300 overseas medical representatives in 33 locations, mainly in Europe and the United States. From this point on, we are aiming for growth through our own development and sales, mainly in the United States, and to this end, we are planning to expand our overseas development and sales bases. While making efforts to develop innovative new medicines, we have become established as a firm presence in the global market for pharmaceutical products by implementing the highest standard of operational efficiency in the industry in order to ‘respond to the medical needs of people everywhere.’
Our U.S. subsidiary, Daiichi Sankyo, Inc. (DSI) has research and development and sales sections, and as the organization that forms the nucleus of our U.S. operations, is expected to grow in the future.
Our European subsidiary, Daiichi Sankyo Europe GmbH (DSE), is headquartered in Munich, Germany, and has around 800 medical representatives in operational bases in 10 European countries.
Having one of the highest penetration rates in Europe, generic medicines play a very important role in the Dutch pharmaceutical market. As this is the principal association for the generics…
While already having worked for Boehringer Ingelheim for quite some time, the end of 2010 marked the completion of your first full year as general manager of this Dutch affiliate.…
Menarini is an extremely proud Italian company in its origins, but also very reliant on international markets. In 2009 approximately 63% of the group’s consolidated revenues came from abroad. What…
When it comes to the pharmaceutical and healthcare industries in the Netherlands, the country has one of the highest generic penetration rates in Europe, it does not have a strong…
WFIA is quite a remarkable organisation that has been, since its inception ten years ago, reporting very good results. The annual results last week showed another strong focus on the…
The Netherlands is famous throughout Europe and the global pharmaceutical community for its research infrastructure – institutes, university hospitals, and public private partnerships. Given this foundation and the size of…
Given the peculiarities of the pharmaceutical industry in the Netherlands, such as the highest generics penetration rate in Europe, a relatively small manufacturing presence and a considerably regulated market, what…
2010 was a very important year for Ferring as it marks the 60th anniversary of the company’s founding. Amongst the various commemorations this year and in hearing the collective experiences…
The Dutch affiliate of Chiesi was established in 2007 when many changes were occurring in the local industry. The new healthcare system policy went into effect and the market was…
“Two traditions one vision” was the phrase used to describe the 2005 merger that formed Daiichi Sankyo as it is today. While referring specifically to a corporate merger, its message…
Agendia has experienced remarkable growth in the seven years since you founded the company. In 2009 you expanded the company’s Amsterdam facilities and, in 2010, you doubled the size of…
Founded in 1997 Actelion is certainly the “new kid on the block” when compared to some of the much older mainstays in the pharmaceutical industry. What would you say was…
See our Cookie Privacy Policy Here
